Mass spectrometry-based peptide sequencing underpins proteomics. Database search confines to predefined candidates, whereas de novo peptide sequencing (DNPS) struggles with incomplete spectra. Existin...

A $274,849 grant will help WSU researcher Jon Oatley advance a promising new male contraceptive that targets sperm development toward human clinical trials.

Injectable peptides are increasingly used without prescriptions for cosmetic and athletic enhancement, driven by digital marketing and social media. While evidence-based, FDA-approved peptides like se...

The actor spoke to GQ about getting in shape for his role on The Terminal List: Dark Wolf and working out alongside his famous brothers.

Phases, founded by husband-and-wife team Lana and Joseph Elie-Meyers, debuts with nine peptide-based treatments tailored to women’s health needs.

Lomeli-Ortega et al. review how peptide-mediated arbitrium signaling enables communication both within and between bacteriophage populations, highlighting how viral crosstalk may influence phage competition, cooperation, and microbial community dynamics while creating opportunities for phage-based technologies.

BB10 Peptide Blend is a high-purity lyophilized formulation combining BPC-157 (5mg) and TB-500 (5mg). This dual-peptide system is designed for advanced laboratory research focusing on tissue repair mechanisms, angiogenesis pathways, and cellular migration processes. This product is intended for research professionals, biotechnology laboratories, and scientific institutions conducting peptide-based studies.

In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.

Click to view the official SEC document.

Glucagon-like peptide-1 (GLP-1)–based therapies have transformed obesity treatment, resulting in significant weight loss and broad metabolic improveme…

AbstractOpen modification search (OMS) strategies have gained popularity in mass spectrometry-based proteomics for identification of peptides carrying unknown or unexpected post-translational modifications. However, most OMS engines report only the overall mass difference between precursor and matched peptide, without explicitly identifying or scoring combinations of modifications at the PSM level. Here, we introduce MS Andrea, a novel OMS search engine that directly identifies and scores combinations of modifications without predefining them. MS Andrea uses a sequence tag-based strategy to filter candidate peptides, evaluated using the MS Amanda scoring function. First fixed modifications only, then combinations of modifications from the Unimod database based on the observed mass shift. We evaluated MS Andrea using a human histone data set and two phosphopeptide data sets (HeLa cells and Arabidopsis thaliana), comparing its performance with MSFragger and Sage. Across data sets, MS Andrea identified the highest number of PSMs at 1% FDR using the standard target-decoy approach while achieving higher or comparable numbers using model-based FDR estimation. Importantly, MS Andrea reports modification identities and sites for up to four modifications at the PSM level. Together, these results demonstrate that MS Andrea enables more detailed, interpretable characterization of peptide modifications while maintaining competitive identification performance in OMS-based proteomics.

AbstractExtracellular vesicles have emerged as crucial components in the advancement of liquid biopsy. However, the efficient isolation of molecularly defined subpopulations remains challenging, limiting the performance of liquid chromatography−tandem mass spectrometry (LC−MS/MS)-based metabolomic analysis. In this study, HER2-targeting peptides were identified via phage display screening against the extracellular domain of HER2 and used to construct a peptide-directed magnetic separation platform (SA@HER2-2-MPMs) for the rapid and selective enrichment of HER2-positive extracellular vesicles. The biotinylated peptide enabled the specific recognition of HER2-enriched EVs’ membranes, while streptavidin-functionalized magnetic polystyrene microspheres facilitated their efficient capture and magnetic separation. The enriched extracellular vesicles were subjected to subsequent metabolite extraction and LC−MS/MS analysis, forming the basis of an integrated workflow for subtype-specific extracellular vesicles isolation and metabolomic profiling. Compared with UC preparations, the peptide-directed workflow yielded lower measured concentrations of selected plasma-associated contaminants and supported downstream LC−MS/MS profiling. Metabolomic analysis revealed disease-associated alterations, and an exploratory predictive reanalysis using nested cross-validation and a held-out internal subset showed high within-cohort discrimination. This study establishes a peptide-directed strategy for isolating molecularly defined EV subpopulations and provides a platform for exploratory metabolic biomarker discovery in HER2-positive breast cancer; independent external validation remains required.

Preparative cIEF enrichment enabled isolation of a low-abundance, poorly resolved basic charge variant identified during routine cIEF analysis. Orthogonal characterization by peptide mapping and SCX-UV–MS revealed incomplete N-terminal pyroglutamate formation and Fc methionine oxidation. Functional assessment demonstrated negligible impact, supporting data-driven cIEF integration strategies and risk-based product quality evaluation. ABSTRACT Biologics such as therapeutic monoclonal antibodies (mAbs) require comprehensive chemistry, manufacturing, and control (CMC) strategies to ensure product safety, efficacy, and consistency. Among these strategies is the comprehensive assessment of product-related variants arising throughout the product development lifecycle. Routine capillary isoelectric focusing (cIEF) analysis of a therapeutic IgG molecule (mAb1) revealed a novel, poorly resolved basic peak at varying abundance across several lots, prompting an investigation. A preparative cIEF-based fractionation strategy with downstream identity characterization by both intact and site-specific mass spectrometry was performed, revealing several basic posttranslational modifications (PTMs), including incomplete N-terminal pyroglutamate conversion and Fc methionine oxidation. These PTMs were ultimately deemed low risk due to their overall low abundance in the unfractionated control and lack of impact on target binding, informing data-driven decision-making for cIEF integration at product release.